These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1398 related articles for article (PubMed ID: 8790483)

  • 41. Trends for in situ and invasive melanoma in Queensland, Australia, 1982-2002.
    Coory M; Baade P; Aitken J; Smithers M; McLeod GR; Ring I
    Cancer Causes Control; 2006 Feb; 17(1):21-7. PubMed ID: 16411049
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Melanoma. Screening and education.
    Ernstoff MS
    Clin Plast Surg; 2000 Jul; 27(3):317-22, vii. PubMed ID: 10941555
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Positive predictive value for presumptive diagnoses of skin cancer and compliance with follow-up among patients attending a community screening program.
    Jonna BP; Delfino RJ; Newman WG; Tope WD
    Prev Med; 1998; 27(4):611-6. PubMed ID: 9672956
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Opportunistic screening strategy for cutaneous melanoma does not change the incidence of nodular and thick lesions nor reduce mortality: a population-based descriptive study in the European region with the highest incidence.
    Bordoni A; Leoni-Parvex S; Peverelli S; Mazzola P; Mazzucchelli L; Spitale A
    Melanoma Res; 2013 Oct; 23(5):402-7. PubMed ID: 23839077
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Epidemiology of cutaneous melanoma. An update.
    Sober AJ; Lew RA; Koh HK; Barnhill RL
    Dermatol Clin; 1991 Oct; 9(4):617-29. PubMed ID: 1934636
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Screening for melanoma.
    Geller AC
    Dermatol Clin; 2002 Oct; 20(4):629-40, viii. PubMed ID: 12380050
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Analysis of public education and the implications with regard to nonprogressive thin melanomas.
    Burton RC
    Curr Opin Oncol; 1995 Mar; 7(2):170-4. PubMed ID: 7756382
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The changing incidence and mortality of melanoma in Australia.
    Marks R
    Recent Results Cancer Res; 2002; 160():113-21. PubMed ID: 12079205
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Skin biopsy rates and incidence of melanoma: population based ecological study.
    Welch HG; Woloshin S; Schwartz LM
    BMJ; 2005 Sep; 331(7515):481. PubMed ID: 16081427
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The many unanswered questions related to the German skin cancer screening programme.
    Stang A; Garbe C; Autier P; Jöckel KH
    Eur J Cancer; 2016 Sep; 64():83-8. PubMed ID: 27371911
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Can primary prevention or selective screening for melanoma be more precisely targeted through general practice? A prospective study to validate a self administered risk score.
    Jackson A; Wilkinson C; Ranger M; Pill R; August P
    BMJ; 1998 Jan; 316(7124):34-8; discussion 38-9. PubMed ID: 9451264
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Melanoma Screening: The Ethics of Over- and Underdiagnosis.
    Wu JH; Negbenebor N
    R I Med J (2013); 2022 Apr; 105(3):17-21. PubMed ID: 35349614
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Screening and prevention measures for melanoma: is there a survival advantage?
    Curiel-Lewandrowski C; Chen SC; Swetter SM;
    Curr Oncol Rep; 2012 Oct; 14(5):458-67. PubMed ID: 22907282
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The effectiveness of skin cancer screening and continuing medical education programs toward increasing the survival of patients with malignant melanoma.
    Reintgen D; Cruse CW; Wells K; Stankard C; Saba H; Schroer K; Cox C; Berman C; Glass F; Alvarez L
    Surg Oncol; 1992 Dec; 1(6):379-84. PubMed ID: 1341274
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Practical considerations of melanoma/skin cancer screening clinics.
    Rampen FH; van Huystee BE; Kiemeney LA
    Dermatology; 1992; 184(3):190-3. PubMed ID: 1392110
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effectiveness of the health campaign for the early diagnosis of cutaneous melanoma in Trentino, Italy.
    Cristofolini M; Bianchi R; Boi S; DeCarli A; Micciolo R; Cristofolini P; Zumiani G
    J Dermatol Surg Oncol; 1993 Feb; 19(2):117-20. PubMed ID: 8429136
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Screening for melanoma: a community survey of prevalence and predictors.
    Girgis A; Campbell EM; Redman S; Sanson-Fisher RW
    Med J Aust; 1991 Mar; 154(5):338-43. PubMed ID: 2017062
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Why are people still dying from melanoma?
    Berwick M
    Arch Dermatol; 1999 Dec; 135(12):1534-6. PubMed ID: 10606064
    [No Abstract]   [Full Text] [Related]  

  • 59. Melanoma Prevention: Comparison of Different Screening Methods for the Selection of a High Risk Population.
    Dubbini N; Puddu A; Salimbeni G; Malloggi S; Gandini D; Massei P; Ferraùto G; Rubino T; Ricci L; Menchini G; Celli M; Ghilardi M; Gianfaldoni R; Gianfaldoni S; Nannipieri A; Romanini A
    Int J Environ Res Public Health; 2021 Feb; 18(4):. PubMed ID: 33671417
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The melanoma epidemic. Is increased surveillance the solution or the problem?
    Swerlick RA; Chen S
    Arch Dermatol; 1996 Aug; 132(8):881-4. PubMed ID: 8712837
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 70.